Skip Navigation


European Heart Journal Advance Access originally published online on July 7, 2006
European Heart Journal 2006 27(16):1891-1892; doi:10.1093/eurheartj/ehl141
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/16/1891    most recent
ehl141v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saxon, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saxon, L. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

More is better with cardiac resynchronization therapy—but is it enough?

Leslie Anne Saxon*

Division of Cardiology, Cardiac Electrophysiology, USC Keck School of Medicine, 1500 San Pablo Street, Los Angeles, CA 90033, USA

* Corresponding author. Tel: +1 323 442 5334; fax: +1 323 442 5399. E-mail address: saxon@usc.edu

This editorial refers to ‘Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [The CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]’{dagger} by J.G.F. Cleland et al., on page 1928

The first 10% of the full text of this article appears below.

The extension phase of the CARE-HF trial results provide important data describing the chronic clinical course of the cardiac resynchronization therapy (CRT) recipient.1 After all, the device is implanted and, unlike a drug that can be stopped, is a relatively permanent part of a patient's treatment. These new data also provide a unique perspective on the use of CRT devices alone, without defibrillating capability (CRT-D). This information, originating in the old world, has practice implications and relevance for the new world. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]
John G.F. Cleland, Jean-Claude Daubert, Erland Erdmann, Nick Freemantle, Daniel Gras, Lukas Kappenberger, Luigi Tavazzi, and on behalf of The CARE-HF Study Investigators
EHJ 2006 27: 1928-1932. [Abstract] [FREE Full Text]